Patents by Inventor Louis William Licamele

Louis William Licamele has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Treatment of circadian rhythm disorders
    Patent number: 11918557
    Abstract: Embodiments of the invention relate to the use of a melatonin agonist in the treatment of free running circadian rhythms in patients, including light perception impaired patients, e.g., blind patients, and to methods of measuring circadian rhythm.
    Type: Grant
    Filed: March 14, 2023
    Date of Patent: March 5, 2024
    Assignee: VANDA PHARMACEUTICALS INC.
    Inventors: Marlene Michelle Dressman, Louis William Licamele, Mihael H. Polymeropoulos
  • Treatment of circadian rhythm disorders
    Patent number: 11918556
    Abstract: Embodiments of the invention relate to the use of a melatonin agonist in the treatment of free running circadian rhythms in patients, including light perception impaired patients, e.g., blind patients, and to methods of measuring circadian rhythm.
    Type: Grant
    Filed: February 15, 2022
    Date of Patent: March 5, 2024
    Assignee: Vanda Pharmaceuticals Inc.
    Inventors: Marlene Michelle Dressman, John Joseph Feeney, Louis William Licamele, Mihael H. Polymeropoulos
  • Treatment of circadian rhythm disorders
    Patent number: 11850229
    Abstract: Embodiments of the invention relate to the use of a melatonin agonist in the treatment of free running circadian rhythms in patients, including light perception impaired patients, e.g., blind patients, and to methods of measuring circadian rhythm.
    Type: Grant
    Filed: February 15, 2022
    Date of Patent: December 26, 2023
    Assignee: Vanda Pharmaceuticals Inc.
    Inventors: Marlene Michelle Dressman, John Joseph Feeney, Louis William Licamele, Mihael H. Polymeropoulos
  • Treatment of circadian rhythm disorders
    Patent number: 11833130
    Abstract: Embodiments of the invention relate to the use of a melatonin agonist in the treatment of free running circadian rhythms in patients, including light perception impaired patients, e.g., blind patients, and to methods of measuring circadian rhythm.
    Type: Grant
    Filed: March 19, 2021
    Date of Patent: December 5, 2023
    Assignee: VANDA PHARMACEUTICALS INC.
    Inventors: Marlene Michelle Dressman, John Joseph Feeney, Louis William Licamele, Mihael H. Polymeropoulos
  • Treatment of circadian rhythm disorders
    Patent number: 11826339
    Abstract: Embodiments of the invention relate to the use of a melatonin agonist in the treatment of free running circadian rhythms in patients, including light perception impaired patients, e.g., blind patients, and to methods of measuring circadian rhythm.
    Type: Grant
    Filed: February 15, 2022
    Date of Patent: November 28, 2023
    Assignee: VANDA PHARMACEUTICALS INC.
    Inventors: Marlene Michelle Dressman, John Joseph Feeney, Louis William Licamele, Mihael H. Polymeropoulos
  • MULTIPLE MYELOMA TREATMENT
    Publication number: 20230346719
    Abstract: The invention relates generally to the treatment of multiple myeloma. One embodiment of the invention provides a method of treating multiple myeloma (MM) in an individual, the method comprising: administering to the individual an effective amount of trichostatin A (TSA).
    Type: Application
    Filed: July 12, 2023
    Publication date: November 2, 2023
    Inventors: Mihael H. Polymeropoulos, Louis William Licamele, Christian Lavedan
  • Multiple myeloma treatment
    Patent number: 11737993
    Abstract: The invention relates generally to the treatment of multiple myeloma. One embodiment of the invention provides a method of treating multiple myeloma (MM) in an individual, the method comprising: administering to the individual an effective amount of trichostatin A (TSA).
    Type: Grant
    Filed: August 26, 2019
    Date of Patent: August 29, 2023
    Assignee: VANDA PHARMACEUTICALS INC.
    Inventors: Mihael H. Polymeropoulos, Louis William Licamele, Christian Lavedan
  • CANCER TREATMENT
    Publication number: 20230257471
    Abstract: The invention relates generally to the treatment of cancer. One embodiment of the invention provides a method of treating cancer in an individual, the method comprising: administering to the individual an effective amount of trichostatin A (TSA).
    Type: Application
    Filed: April 25, 2023
    Publication date: August 17, 2023
    Inventors: Mihael H. Polymeropoulos, Louis William Licamele, Christian Lavedan
  • TREATMENT OF CIRCADIAN RHYTHM DISORDERS
    Publication number: 20230210810
    Abstract: Embodiments of the invention relate to the use of a melatonin agonist in the treatment of free running circadian rhythms in patients, including light perception impaired patients, e.g., blind patients, and to methods of measuring circadian rhythm.
    Type: Application
    Filed: March 14, 2023
    Publication date: July 6, 2023
    Inventors: Marlene Michelle Dressman, Louis William Licamele, Mihael H. Polymeropoulos
  • Cancer treatment
    Patent number: 11667718
    Abstract: The invention relates generally to the treatment of cancer. One embodiment of the invention provides a method of treating cancer in an individual, the method comprising: administering to the individual an effective amount of trichostatin A (TSA).
    Type: Grant
    Filed: June 28, 2021
    Date of Patent: June 6, 2023
    Assignee: Vanda Pharmaceuticals Inc.
    Inventors: Mihael H. Polymeropoulos, Louis William Licamele, Christian Lavedan
  • Treatment of circadian rhythm disorders
    Patent number: 11633377
    Abstract: Embodiments of the invention relate to the use of a melatonin agonist in the treatment of free running circadian rhythms in patients, including light perception impaired patients, e.g., blind patients, and to methods of measuring circadian rhythm.
    Type: Grant
    Filed: February 8, 2021
    Date of Patent: April 25, 2023
    Assignee: Vanda Pharmaceuticals Inc.
    Inventors: Marlene Michelle Dressman, Louis William Licamele, Mihael H. Polymeropoulos
  • TREATMENT OF CYR61- AND VEGF-MEDIATED CONDITIONS
    Publication number: 20220401464
    Abstract: The invention relates generally to the treatment of CYR61- and VEGF-mediated conditions and, more particularly to the treatment of such conditions by administering to an individual a CYR61 downregulator. In one embodiment, the invention provides a method of treating a CYR61-mediated condition in an individual in need of such treatment, the method comprising: administering to the individual an effective amount of at least one CYR61 downregulator (CYR61DR), wherein the effective amount is an amount sufficient to decrease expression of the CYR61 gene in the individual.
    Type: Application
    Filed: August 25, 2022
    Publication date: December 22, 2022
    Inventors: Mihael H. POLYMEROPOULOS, Louis William LICAMELE, Christian LAVEDAN
  • Treatment of CYR61- and VEGF-mediated conditions
    Patent number: 11458154
    Abstract: The invention relates generally to the treatment of CYR61- and VEGF-mediated conditions and, more particularly to the treatment of such conditions by administering to an individual a CYR61 downregulator. In one embodiment, the invention provides a method of treating a CYR61-mediated condition in an individual in need of such treatment, the method comprising: administering to the individual an effective amount of at least one CYR61 downregulator (CYR61DR), wherein the effective amount is an amount sufficient to decrease expression of the CYR61 gene in the individual.
    Type: Grant
    Filed: September 4, 2014
    Date of Patent: October 4, 2022
    Assignee: VANDA PHARMACEUTICALS INC.
    Inventors: Mihael H. Polymeropoulos, Louis William Licamele, Christian Lavedan
  • METHOD OF TREATMENT WITH TRADIPITANT
    Publication number: 20220226295
    Abstract: This application relates to a method of treatment with the NK-1 antagonist, tradipitant.
    Type: Application
    Filed: April 6, 2022
    Publication date: July 21, 2022
    Inventors: Mihael H. Polymeropoulos, Louis William Licamele
  • TREATMENT OF CIRCADIAN RHYTHM DISORDERS
    Publication number: 20220175716
    Abstract: Embodiments of the invention relate to the use of a melatonin agonist in the treatment of free running circadian rhythms in patients, including light perception impaired patients, e.g., blind patients, and to methods of measuring circadian rhythm.
    Type: Application
    Filed: February 15, 2022
    Publication date: June 9, 2022
    Inventors: Marlene Michelle Dressman, John Joseph Feeney, Louis William Licamele, Mihael H. Polymeropoulos
  • TREATMENT OF CIRCADIAN RHYTHM DISORDERS
    Publication number: 20220168264
    Abstract: Embodiments of the invention relate to the use of a melatonin agonist in the treatment of free running circadian rhythms in patients, including light perception impaired patients, e.g., blind patients, and to methods of measuring circadian rhythm.
    Type: Application
    Filed: February 15, 2022
    Publication date: June 2, 2022
    Inventors: Marlene Michelle Dressman, John Joseph Feeney, Louis William Licamele, Mihael H. Polymeropoulos
  • TREATMENT OF CIRCADIAN RHYTHM DISORDERS
    Publication number: 20220168263
    Abstract: Embodiments of the invention relate to the use of a melatonin agonist in the treatment of free running circadian rhythms in patients, including light perception impaired patients, e.g., blind patients, and to methods of measuring circadian rhythm.
    Type: Application
    Filed: February 15, 2022
    Publication date: June 2, 2022
    Inventors: Marlene Michelle Dressman, John Joseph Feeney, Louis William Licamele, Mihael H. Polymeropoulos
  • Method of treatment with tradipitant
    Patent number: 11324735
    Abstract: This application relates to a method of treatment with tradipitant, and more particularly, to a method of treatment of pruritus with tradipitant.
    Type: Grant
    Filed: July 31, 2020
    Date of Patent: May 10, 2022
    Assignee: Vanda Pharmaceuticals Inc.
    Inventors: Mihael H. Polymeropoulos, Louis William Licamele
  • Treatment of circadian rhythm disorders
    Patent number: 11285129
    Abstract: Embodiments of the invention relate to the use of a melatonin agonist in the treatment of free running circadian rhythms in patients, including light perception impaired patients, e.g., blind patients, and to methods of measuring circadian rhythm.
    Type: Grant
    Filed: July 6, 2021
    Date of Patent: March 29, 2022
    Assignee: VANDA PHARMACEUTICALS INC.
    Inventors: Marlene Michelle Dressman, John Joseph Feeney, Louis William Licamele, Mihael H. Polymeropoulos
  • TREATMENT OF CIRCADIAN RHYTHM DISORDERS
    Publication number: 20210330634
    Abstract: Embodiments of the invention relate to the use of a melatonin agonist in the treatment of free running circadian rhythms in patients, including light perception impaired patients, e.g., blind patients, and to methods of measuring circadian rhythm.
    Type: Application
    Filed: July 6, 2021
    Publication date: October 28, 2021
    Inventors: Marlene Michelle Dressman, John Joseph Feeney, Louis William Licamele, Mihael H. Polymeropoulos